Previous 10 | Next 10 |
Design Therapeutics has filed proposed terms for a $228 million IPO. The firm is developing treatments for Friedreich ataxia and myotonic dystrophy. DSGN is still at a preclinical stage of development and is seeking a high valuation at IPO; the IPO may be more suited to institutio...
Image source: The Motley Fool. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Q4 2020 Earnings Call Mar 1, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Reata Pharmaceuticals, Inc. (RETA) Q4 2020 Earnings Call Transcr...
Reata Pharmaceuticals, Inc. (RETA) Q4 2020 Earnings Conference Call March 01, 2021 08:30 A.M. ET Company Participants Vinny Jindal - VP, Corporate Communications & Strategy Warren Huff - President & CEO Colin Meyer - EVP and Chief Research & Development Officer Manmeet S. Soni - E...
Reata Pharmaceuticals ([[RETA]] +5.9%) posted fourth-quarter results that beat Wall Street estimates and said that its existing cash and cash equivalents will be sufficient to enable it to fund operations through mid-2024.Revenue of $3.2M (+19.9% Y/Y), beat estimates by $2M.The company's...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
Reata Pharmaceuticals (RETA) has submitted a New Drug Application ((NDA)) for bardoxolone methyl to the FDA for the treatment of chronic kidney disease ((CKD)) caused by Alport syndrome. The submission includes a request for Priority Review, which, if granted, would shorten the FDA’s r...
Reata Pharmaceuticals (RETA): Q4 Non-GAAP EPS of -$1.25 beats by $0.45; GAAP EPS of -$1.90 beats by $0.26.Revenue of $3.2M (+19.9% Y/Y) beats by $2M.Press Release For further details see: Reata Pharmaceuticals EPS beats by $0.45, beats on revenue
ANNOUNCES FIRST NDA SUBMISSION FOR COMPANY’S LEAD PROGRAM: BARDOXOLONE IN ALPORT SYNDROME PROVIDES UPDATE ON FALCON STUDY OF BARDOXOLONE IN ADPKD ANNOUNCES FIRST PATIENT ENROLLED IN MERLIN TRIAL OF BARDOXOLONE IN CHRONIC KIDNEY DISEASE AT RISK FOR RAPID ...
PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it has submitted a New Drug Application (“NDA ...
Reata Pharmaceuticals (NASDAQ:RETA) is scheduled to announce Q4 earnings results on Monday, March 1st, before market open.The consensus EPS Estimate is -$1.70 (-6.9% Y/Y) and the consensus Revenue Estimate is $1.2M (-55.1% Y/Y).Over the last 2 years, RETA has beaten EPS estimates 38% of the t...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...